Does CARFILZOMIB Cause Infusion site extravasation? 52 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 52 reports of Infusion site extravasation have been filed in association with CARFILZOMIB (KYPROLIS). This represents 0.2% of all adverse event reports for CARFILZOMIB.
52
Reports of Infusion site extravasation with CARFILZOMIB
0.2%
of all CARFILZOMIB reports
1
Deaths
11
Hospitalizations
How Dangerous Is Infusion site extravasation From CARFILZOMIB?
Of the 52 reports, 1 (1.9%) resulted in death, 11 (21.2%) required hospitalization, and 1 (1.9%) were considered life-threatening.
Is Infusion site extravasation Listed in the Official Label?
Yes, Infusion site extravasation is listed as a known adverse reaction in the official FDA drug label for CARFILZOMIB.
What Other Side Effects Does CARFILZOMIB Cause?
Plasma cell myeloma (2,238)
Off label use (2,120)
Death (1,442)
Thrombocytopenia (1,265)
Fatigue (1,048)
Pneumonia (1,016)
Pyrexia (969)
Anaemia (910)
Dyspnoea (881)
Neutropenia (874)
What Other Drugs Cause Infusion site extravasation?
HUMAN IMMUNOGLOBULIN G (822)
INFLIXIMAB (435)
INFLIXIMAB-DYYB (328)
TREPROSTINIL (256)
VEDOLIZUMAB (199)
HUMAN IMMUNOGLOBULIN G\HYALURONIDASE RECOMBINANT HUMAN (185)
REMDESIVIR (144)
FERRIC CARBOXYMALTOSE (118)
RITUXIMAB (82)
NATALIZUMAB (70)
Which CARFILZOMIB Alternatives Have Lower Infusion site extravasation Risk?
CARFILZOMIB vs CARGLUMIC ACID
CARFILZOMIB vs CARIPRAZINE
CARFILZOMIB vs CARISOPRODOL
CARFILZOMIB vs CARMUSTINE
CARFILZOMIB vs CARTEOLOL